CELG : Analysis & Opinions

  1. TrovaGene Partners with Leading Cancer Research Institutes - ...

    January 26, 2015
    TrovaGene Inc. (TROV) recently announced a number of collaborations with eminent research institutes around the world.
  2. Novartis' Psoriasis Drug Cosentyx Gets FDA Approval - Analyst ...

    January 22, 2015
    Novartis (NVS) announced that the FDA has approved Cosentyx for the treatment of moderate-to-severe plaque psoriasis in adult ...
  3. Keryx to Raise $110 Million Through Issuance of Shares - Analyst ...

    January 22, 2015
    Keryx (KERX) will be raising $110 million through the issuance of the shares with plans to invest the funds on the ongoing ...
  4. Arena Pharmaceuticals to Raise Fund Via Share Issuance - Analyst ...

    January 22, 2015
    Arena Pharmaceuticals (ARNA) announced that it will be selling 21 million shares in an underwritten public offering of common ...
  5. Celgene to Use Zymeworks' Azymetric Platform for New Drugs - ...

    January 22, 2015
    Celgene (CELG) inked a deal with Zymeworks for the research, development and commercialization of bi-specific antibody therapeutics.
  6. Alnylam to Raise $450 Million Through Issuance of Shares - Analyst ...

    January 21, 2015
    Alnylam (ALNY) will be raising $450 million through the issuance of shares with plans to invest the funds across its pipeline.
  7. Affymetrix Hits 52-Week High on Strong Top-Line Growth - Analyst ...

    January 21, 2015
    Shares of Affymetrix Inc. (AFFX) scaled a new 52-week high of $11.89 on Jan 20, eventually closing at $11.65.
  8. Biotech Stock Roundup: EU Approvals for AbbVie & Celgene Drugs, ...

    January 21, 2015
    The hepatitis C virus (HCV) pricing battle is heating up with Gilead (GILD) signing on with quite a few PBMs and health care ...
  9. Stock Market News for January 21, 2015 - Market News

    January 21, 2015
    Benchmarks ended Tuesday’s choppy trading session in the green led by gains from technology shares
  10. Supernus Downgraded as Lead Drugs Face Patent Challenges - Analyst ...

    January 20, 2015
    Zacks Investment Research downgraded Supernus Pharmaceuticals (SUPN) to a Zacks Rank #4 (Sell) on Jan 20.
  11. J&J Beats on Q4 Earnings, Revenues Hit by Currency - Analyst ...

    January 20, 2015
    J&J's fourth quarter results were mixed with the company beating on earnings and missing on revenues.
  12. Celgene Up as Otezla Gains EU Approval for Two Indications - ...

    January 19, 2015
    Celgene Corporation announced that the European Commission has granted approval to Otezla for two therapeutic indications.
  13. The Biggest Biotech Companies

    January 15, 2015
    These biotech firms want to revolutionize medicine. If successful, they may see high profits, but investing in these companies ...
  14. Biotech Stock Roundup: Shire to Acquire NPSP, Celgene & Pharmacyclics ...

    January 14, 2015
    Preliminary fourth quarter results and expectations for 2015 were key highlights in the biotech sector.
  15. Celgene's Preliminary Results & 2015 Outlook Encouraging - Analyst ...

    January 13, 2015
    Celgene Corporation (CELG) provided encouraging guidance for 2015.
  16. Stock Market News for December 26, 2014 - Market News

    December 26, 2014
    Markets ended modestly higher on Wednesday’s abbreviated trading session banking on initial claims dropping to a seven-week ...
  17. 4 Biotech Stocks that Doubled in 2014 - Analyst Blog

    December 26, 2014
    Promising pipeline candidates, progress on the regulatory front and interesting research platforms helped these 4 biotech ...
  18. Celgene Corporation (CELG): New Analyst Report from Zacks Equity ...

    December 26, 2014
    Celgene's third quarter 2014 adjusted earnings of $0.88 per share surpassed the Zacks Consensus Estimate by 6 cents. Revlimid's ...
  19. Stock Market News for December 24, 2014 - Market News

    December 24, 2014
    Benchmarks mostly settled in the green on Tuesday banking on better-than-expected revision to third quarter GDP numbers
  20. Celgene Gets Positive CHMP Recommendation for Revlimid - Analyst ...

    December 22, 2014
    Celgene Corporation announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has rendered ...
  21. 4 Top Ranked Biotech Stocks that Beat the Market in 2014 - Analyst ...

    December 16, 2014
    Despite the sell-off in late March, the biotech sector bounced back thanks to important product approvals, mergers and acquisitions, ...
  22. Who are Amgen Inc.'s (AMGN) main competitors?

    August 27, 2014
    Biotech giant Amgen (AMGN) list of competitors is lengthy and formidable. Learn the major companies Amgen competes with.
  23. Bull of the Day: Epizyme (EPZM) - Bull of the Day

    August 21, 2014
    Bull of the Day: Epizyme (EPZM) - Bull of the Day
  24. Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook

    March 25, 2014
    Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
  25. Four Stocks Setting Up For A Move Lower

    February 12, 2014
    These four stocks have recently broken out of chart patterns, indicting further moves in the breakout direction.
  26. Biotech Stock Roundup: Amgen Data Looks Good, CANF Tumbles - ...

    January 8, 2014
    Biotech Stock Roundup: Amgen Data Looks Good, CANF Tumbles - Industry Outlook
  27. Gilead Sciences Leads In Rising Short Interest Among Biotechs

    November 12, 2013
    Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Alexion Pharmaceuticals ...
  28. Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, ...

    September 14, 2013
    Declining short interest in Alexion Pharmaceuticals (NASDAQ: PCYC) bucked the trend among leading biotech and emerging pharmaceutical ...
  29. Amgen Sweetens The Bid And Secures Onyx

    August 26, 2013
    Amgen finalizes a value-additive deal for Onyx
  30. Pfizer Looking A Little Tired

    July 30, 2013
    Pfizer gets a boost from better margins, but the growth outlook is pretty feeble.
  31. 8 Stages Of New Drug Development

    July 29, 2013
    Understanding biotech data isn't easy. What is a clinical trial, what are the various phases, and why do the results of these ...
  32. Celgene Only Getting Started, But The Street's Already Looking ...

    July 26, 2013
    Biotech valuations are into the nose-bleed zone, but Celgene continues to execute very well.
  33. Amgen Puts Onyx Pharmaceuticals In Play

    July 2, 2013
    An unsolicited $120/share bid has sent Onyx soaring and rival bidders circling.
  34. Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, ...

    June 26, 2013
    Among biotech and emerging pharmaceutical companies, Celgene (NASDAQ: CELG) and saw the most significant rise in short interest ...
  35. Amgen Chased By The Bubble

    May 8, 2013
    Amgen really needs the pipeline to come through to support this valuation.
  36. MedTech Industry Stock Outlook - Jan 2013 - Zacks Analyst Interviews

    January 29, 2013
    We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the worldwide ...
  37. BMY/ABT Present Oncology Data - Analyst Blog

    December 12, 2012
    Bristol-Myers Squibb Company (BMY) and partner Abbott Laboratories (ABT) recently presented data on their oncology candidate ...
  38. Amgen and Other Healthcare Stocks Making Big Moves on October ...

    October 19, 2012
    The market is having a bad day so far: the Nasdaq has slipped 1.6%; the S&P 500 is trading down 1%; and the Dow is down ...
  39. Playing A Biotech Breakout

    February 15, 2012
    Strong pipelines for the biotech sector as well as a wave of merger activity, have investors flocking to the stocks.
  40. XOMA Rearranges The Deck Chairs One More Time

    September 2, 2011
    XOMA changes management again, but should anybody care?
  41. Are Buybacks A Bad Sign?

    August 24, 2011
    Investors celebrate buybacks, but there is a cost to every decision.
  42. A Dull ASCO And The Usual Sell-Off

    June 7, 2011
    Investors shouldn't be spooked by the normal post-ASCO sell-off
  43. A Deal At Last For Sanofi And Genzyme

    February 18, 2011
    Though Sanofi finally got its way in acquiring Genzyme, time will determine if stockholders will truly benefit.
  44. There Is Life After Death, At Least In Biotech

    June 22, 2010
    Clinical failure is not the end of the story for all biotechs. How do some survive while others disappear?
  45. The Best Performing Stocks Of The Decade

    June 9, 2009
    Investors who were able to see past the losses and volatility that some of these companies had in the beginning were amply ...
  46. Biotech ETFs Under The Microscope

    July 24, 2008
    Biotech ETFs have been immune to the falling stock market. We examine three top performing funds to find a surprising long-term ...
Trading Center